BIO-TECHNE Corp Net Cash Provided by (Used in) Financing Activities, Continuing Operations
BIO-TECHNE Corp (TECH) reported Net Cash Provided by (Used in) Financing Activities, Continuing Operations of $189.39 million for the 12-month period ending 2017-06-30, per its 10-K filed 2017-09-07.
Discontinued › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations · last filed 2017-09-07
- BIO-TECHNE Corp net cash provided by (used in) financing activities, continuing operations for the quarter ending 2017-06-30 was -$16.62M.
- BIO-TECHNE Corp net cash provided by (used in) financing activities, continuing operations for the quarter ending 2017-03-31 was -$24.44M.
- BIO-TECHNE Corp net cash provided by (used in) financing activities, continuing operations for the quarter ending 2016-12-31 was -$11.88M.
- BIO-TECHNE Corp net cash provided by (used in) financing activities, continuing operations for the quarter ending 2016-09-30 was $242.33M, a 478.85% increase year-over-year.
- BIO-TECHNE Corp net cash provided by (used in) financing activities, continuing operations for fiscal 2017 was $189.39M.
- BIO-TECHNE Corp net cash provided by (used in) financing activities, continuing operations for fiscal 2016 was -$23.08M, a 173.81% decline from fiscal 2015.
- BIO-TECHNE Corp net cash provided by (used in) financing activities, continuing operations for fiscal 2015 was $31.27M.
- BIO-TECHNE Corp net cash provided by (used in) financing activities, continuing operations for fiscal 2014 was -$36.81M.
| Period end | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 12 month | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 12 month as first filed |
|---|---|---|---|---|---|
| 2017-06-30 | -$16.62M derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-07 | -$41.06M derived: sum of 2 quarters · filed 2017-09-07 | -$52.95M derived: sum of 3 quarters · filed 2017-09-07 | $189.39M 10-K · filed 2017-09-07 | |
| 2017-03-31 | -$24.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-05-10 | -$36.32M derived: sum of 2 quarters · filed 2017-05-10 | $206.01M 10-Q · filed 2017-05-10 | $173.96M derived: sum of 4 quarters · filed 2017-09-07 | |
| 2016-12-31 | -$11.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-09 | $230.45M 10-Q · filed 2017-02-09 | $198.40M derived: sum of 3 quarters · filed 2017-09-07 | $178.87M derived: sum of 4 quarters · filed 2017-09-07 | |
| 2016-09-30 | $242.33M 10-Q · filed 2016-11-09 | $210.29M derived: sum of 2 quarters · filed 2017-09-07 | $190.75M derived: sum of 3 quarters · filed 2017-09-07 | $177.39M derived: sum of 4 quarters · filed 2017-09-07 | |
| 2016-06-30 | -$32.05M derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-07 | -$51.58M derived: sum of 2 quarters · filed 2017-09-07 | -$64.95M derived: sum of 3 quarters · filed 2017-09-07 | -$23.08M 10-K · filed 2017-09-07 | |
| 2016-03-31 | -$19.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-05-10 | -$32.90M derived: sum of 2 quarters · filed 2017-05-10 | $8.96M 10-Q · filed 2017-05-10 | -$76.71M derived: sum of 4 quarters · filed 2017-09-07 | |
| 2015-12-31 | -$13.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-09 | $28.50M 10-Q · filed 2017-02-09 | -$57.18M derived: sum of 3 quarters · filed 2017-09-07 | -$68.18M derived: sum of 4 quarters · filed 2017-09-07 | |
| 2015-09-30 | $41.87M 10-Q · filed 2016-11-09 | -$43.81M derived: sum of 2 quarters · filed 2017-09-07 | -$54.81M derived: sum of 3 quarters · filed 2017-09-07 | -$29.33M derived: sum of 4 quarters · filed 2017-09-07 | |
| 2015-06-30 | -$85.68M derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-07 | -$96.68M derived: sum of 2 quarters · filed 2017-09-07 | -$71.19M derived: sum of 3 quarters · filed 2017-09-07 | $31.27M 10-K · filed 2017-09-07 | $31.28M 10-K · filed 2015-08-31 |
| 2015-03-31 | -$11.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-05-10 | $14.48M derived: sum of 2 quarters · filed 2016-05-10 | $116.95M 10-Q · filed 2016-05-10 | $108.94M derived: sum of 4 quarters · filed 2016-08-29 | |
| 2014-12-31 | $25.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-02-09 | $127.95M 10-Q · filed 2016-02-09 | $119.94M derived: sum of 3 quarters · filed 2016-08-29 | $110.03M derived: sum of 4 quarters · filed 2016-08-29 | |
| 2014-09-30 | $102.47M 10-Q · filed 2015-11-09 | $94.46M derived: sum of 2 quarters · filed 2016-08-29 | $84.55M derived: sum of 3 quarters · filed 2016-08-29 | $75.57M derived: sum of 4 quarters · filed 2016-08-29 | |
| 2014-06-30 | -$8.01M derived: 10-K 12 month − 10-Q 9 month · filed 2016-08-29 | -$17.92M derived: sum of 2 quarters · filed 2016-08-29 | -$26.90M derived: sum of 3 quarters · filed 2016-08-29 | -$36.81M 10-K · filed 2016-08-29 | |
| 2014-03-31 | -$9.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-05-11 | -$18.89M derived: sum of 2 quarters · filed 2015-05-11 | -$28.80M 10-Q · filed 2015-05-11 | ||
| 2013-12-31 | -$8.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-02-09 | -$18.89M 10-Q · filed 2015-02-09 | |||
| 2013-09-30 | -$9.90M 10-Q · filed 2014-11-10 | ||||
| 2013-06-30 | -$44.68M 10-K · filed 2015-08-31 | ||||
| 2012-06-30 | -$64.63M 10-K · filed 2014-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |